162 related articles for article (PubMed ID: 2191681)
1. Lymphokine gene therapy for cancer.
Russell SJ
Immunol Today; 1990 Jun; 11(6):196-200. PubMed ID: 2191681
[TBL] [Abstract][Full Text] [Related]
2. Approaches to immunotherapy of cancer: characterization of lymphokines as second signals for cytotoxic T-cell generation.
Bertagnolli MM; Herrmann SH; Pinto VM; Schoof DD; Eberlein TJ
Surgery; 1991 Sep; 110(3):459-68. PubMed ID: 1887370
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells.
van Haelst-Pisani CM; Pisani RJ; Kovach JS
Mayo Clin Proc; 1989 Apr; 64(4):451-65. PubMed ID: 2654502
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity in lymphokine profiles of CD4+ and CD8+ T cells and clones activated in vivo and in vitro.
Kelso A; Troutt AB; Maraskovsky E; Gough NM; Morris L; Pech MH; Thomson JA
Immunol Rev; 1991 Oct; 123():85-114. PubMed ID: 1684785
[TBL] [Abstract][Full Text] [Related]
5. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.
Gastl G; Finstad CL; Guarini A; Bosl G; Gilboa E; Bander NH; Gansbacher B
Cancer Res; 1992 Nov; 52(22):6229-36. PubMed ID: 1423266
[TBL] [Abstract][Full Text] [Related]
6. Cognate interactions between helper T cells and B cells. I. Cloning and helper activity of a lymphokine-dependent helper T cell clone (Th-3).
Noelle RJ; McCann J
J Mol Cell Immunol; 1989; 4(3):161-73; discussion 173-5. PubMed ID: 2527511
[TBL] [Abstract][Full Text] [Related]
7. Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
Sivanandham M; Scoggin SD; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):114-8. PubMed ID: 1642399
[TBL] [Abstract][Full Text] [Related]
8. Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.
Belldegrun A; Kasid A; Uppenkamp M; Topalian SL; Rosenberg SA
J Immunol; 1989 Jun; 142(12):4520-6. PubMed ID: 2723437
[TBL] [Abstract][Full Text] [Related]
9. [Lymphokines].
Okuno K; Hamaoka T
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2053-64. PubMed ID: 6764096
[TBL] [Abstract][Full Text] [Related]
10. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
11. Production of multiple lymphokines by the A20.1 B cell lymphoma after cross-linking of membrane Ig by immobilized anti-Ig.
Justement LB; Kreiger J; Cambier JC
J Immunol; 1989 Aug; 143(3):881-9. PubMed ID: 2663989
[TBL] [Abstract][Full Text] [Related]
12. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.
Pulley MS; Nagendran V; Edwards JM; Dumonde DC
Lymphokine Res; 1986; 5 Suppl 1():S157-63. PubMed ID: 3784610
[TBL] [Abstract][Full Text] [Related]
13. Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo.
Lafreniere R; Rosenstein MS; Rosenberg SA
J Immunol Methods; 1986 Nov; 94(1-2):37-49. PubMed ID: 2878049
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
15. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
Rosenberg SA; Lotze MT; Mulé JJ
Ann Intern Med; 1988 Jun; 108(6):853-64. PubMed ID: 3285747
[TBL] [Abstract][Full Text] [Related]
16. B cell lymphokines in human systemic lupus erythematosus.
Tan PL; Blumenstein M; Yeoman S; Watson JD
Ann Rheum Dis; 1989 Nov; 48(11):941-5. PubMed ID: 2596884
[TBL] [Abstract][Full Text] [Related]
17. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
18. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
Rosenberg SA
Ann Surg; 1988 Aug; 208(2):121-35. PubMed ID: 3041925
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-mediated immunotherapy studies in mouse tumor systems.
Papermaster BW; Gilliland CD; McEntire JE; Smith ME; Buchok SJ
Cancer; 1980 Mar; 45(5 Suppl):1248-53. PubMed ID: 7357517
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.
Rosenberg SA
Important Adv Oncol; 1988; ():217-57. PubMed ID: 3042605
[No Abstract] [Full Text] [Related]
[Next] [New Search]
